Vanguard Portfolio Management
DSGN icon

Vanguard Portfolio Management’s Design Therapeutics DSGN Stock Holding History

Vanguard Portfolio Management’s Portfolio DSGN Stock Details DSGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.64M Buy
251,442
+112,877
+81% +$1.41M ﹤0.01% 2532
2026
Q1 		$1.47M Buy
+138,565
New +$1.4M ﹤0.01% 2677

Other funds holding DSGN

SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management's DSGN Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Design Therapeutics (DSGN) stake by 81% in Q2 2026, buying an estimated $1.41M and bringing the position to 251,442 shares worth $3.64M. The position accounts for ﹤0.01% of the portfolio, ranked #2532.

Vanguard Portfolio Management first reported a position in DSGN in Q1 2026 and has held it in 2 quarters since. 136 funds tracked by Wall St. Rank hold DSGN as of Q2 2026.

  • Vanguard Portfolio Management held 251,442 shares of Design Therapeutics worth $3.64M as of Q2 2026.
  • Vanguard Portfolio Management bought 112,877 Design Therapeutics shares in Q2 2026, an estimated $1.41M.
  • Design Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #2532 holding.
  • Vanguard Portfolio Management first reported a position in Design Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • 136 funds tracked by Wall St. Rank held Design Therapeutics as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.